Description：ELISA for the detection of Acapatamab in human serum and plasma.
Lead time for this kit is 5 weeks.
About the kit： - Uses anti-idiotypic monoclonal antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity.
- Recovery rates are between 85 - 115％ - Validated as per US FDA guidelines for Bioassays - Developed using the innovator drug as calibrator - Shelf life： 1 year.Acapatamab is a half-life extended （HLE） BiTE immune-oncology therapy that targets PSMA-expressing cancer cells being investigated in prostate cancer and non-small cell lung cancer （NSCLC）.
A bispecific antibody, it simultaneously binds to PSMA on tumor cells and CD3 on T cells, and is designed to engage patients' own T cells to fight cancer.
Multiple clinical trials are on-going to test the efficacy of Acapatamab.
